On July 1, the Centers for Medicare and Medicaid Services (CMS) launched a temporary program to cover GLP-1 agonist drugs for obese Medicare beneficiaries. The program is called the Medicare GLP-1 Bridge and will allow eligible beneficiaries to access the drugs for a $50 monthly copayment.
The program is slated to run from July 2026...
As insurance companies raise flags about the cost of GLP-1 weight loss drugs in coordination with government payer programs, the Trump administration has rescinded its plan to have insurance companies fund coverage of the obesity drugs and will have Medicare pay the cost instead.
Last year, the White House announced a landmark deal...National News
Last week, the Centers for Medicare and Medicaid Services released requests for applications (RFAs) for state Medicaid plans and Medicare Part D plans that would be interested in participating in the new Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model which focuses on lowering prices for GLP-1 drugs....
The Centers for Medicare and Medicaid Services announced a new drug pricing model to allow state Medicaid agencies and Medicare Part D plans to cover GLP-1 drugs at lower costs. The announcement comes as Novo Nordisk seeks to regain lost ground in the race for dominance in the American GLP-1 market and its pill version of Wegovy is...
